Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.
Animals
Cell Adhesion
Cell Line, Tumor
Epithelial-Mesenchymal Transition
Extracellular Vesicles
/ metabolism
Gene Expression Regulation, Neoplastic
Humans
Integrin alphaV
/ metabolism
Male
Mice
Mice, Nude
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Transplantation
Prostatic Neoplasms
/ metabolism
Proteomics
/ methods
Proto-Oncogene Proteins c-akt
/ metabolism
Up-Regulation
AKT
Alpha-V integrin
Extracellular vesicles
Oncosomes
Prostate cancer
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
18 Jul 2019
18 Jul 2019
Historique:
received:
08
04
2019
accepted:
09
07
2019
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
14
1
2020
Statut:
epublish
Résumé
Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype. Immunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry. We found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status. Overall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.
Sections du résumé
BACKGROUND
BACKGROUND
Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype.
METHODS
METHODS
Immunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry.
RESULTS
RESULTS
We found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status.
CONCLUSIONS
CONCLUSIONS
Overall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.
Identifiants
pubmed: 31319863
doi: 10.1186/s13046-019-1317-6
pii: 10.1186/s13046-019-1317-6
pmc: PMC6639931
doi:
Substances chimiques
Integrin alphaV
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317Subventions
Organisme : NCI NIH HHS
ID : R01 CA234557
Pays : United States
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : Fellowships AIRC-FIRC for Italy 19586
Organisme : Ministero della Salute
ID : Institutional Ricerca Corrente funds - Project M3_6
Références
FASEB J. 2001 Sep;15(11):1953-62
pubmed: 11532975
Int J Cancer. 2004 Dec 10;112(5):738-46
pubmed: 15386367
Endocr Relat Cancer. 2006 Mar;13(1):7-26
pubmed: 16601276
J Cell Biol. 2007 Jun 4;177(5):927-39
pubmed: 17548516
Int J Cancer. 2007 Oct 1;121(7):1424-32
pubmed: 17551921
Clin Cancer Res. 2008 Sep 15;14(18):5649-55
pubmed: 18794071
Front Biosci (Landmark Ed). 2009 Jan 01;14:2494-503
pubmed: 19273214
Cancer Res. 2009 Jul 1;69(13):5601-9
pubmed: 19549916
Int J Cancer. 2010 Sep 1;127(5):1081-95
pubmed: 20027628
Curr Pharm Des. 2011;17(19):1944-61
pubmed: 21711235
Oncogene. 2012 Nov 8;31(45):4740-9
pubmed: 22266864
Br J Cancer. 2012 Aug 7;107(4):713-23
pubmed: 22767145
Am J Pathol. 2012 Nov;181(5):1573-84
pubmed: 23022210
Clin Cancer Res. 2013 Apr 1;19(7):1760-72
pubmed: 23287563
Cell Death Dis. 2013 May 23;4:e641
pubmed: 23703386
IUBMB Life. 2013 Oct;65(10):807-18
pubmed: 24030926
Cell Cycle. 2013 Nov 15;12(22):3526-36
pubmed: 24091630
Cell Death Dis. 2013 Oct 24;4:e878
pubmed: 24157872
Cancer Res. 2014 Mar 1;74(5):1598-608
pubmed: 24385215
Asian J Androl. 2014 Jul-Aug;16(4):530-5
pubmed: 24589458
Oncotarget. 2014 Mar 30;5(6):1538-53
pubmed: 24681666
Oncotarget. 2015 Mar 10;6(7):5324-41
pubmed: 25481874
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
J Biol Chem. 2015 Feb 20;290(8):4545-51
pubmed: 25568317
Oncotarget. 2015 May 10;6(13):11327-41
pubmed: 25857301
Minerva Urol Nefrol. 2015 Sep;67(3):211-31
pubmed: 26054411
Mol Med Rep. 2015 Nov;12(5):6702-10
pubmed: 26299938
Oncotarget. 2015 Sep 22;6(28):25076-92
pubmed: 26312765
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Int J Mol Sci. 2016 Feb 06;17(2):175
pubmed: 26861306
J Extracell Vesicles. 2016 Sep 27;5:33109
pubmed: 27680302
Int J Mol Sci. 2016 Dec 06;17(12):
pubmed: 27929432
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
Dev Dyn. 2018 Mar;247(3):382-395
pubmed: 28722327
Cancers (Basel). 2017 Jul 26;9(8):null
pubmed: 28933725
Oncogenesis. 2017 Oct 9;6(10):e388
pubmed: 28991260
J Exp Clin Cancer Res. 2017 Dec 08;36(1):180
pubmed: 29216889
Cell Death Dis. 2018 May 9;9(5):523
pubmed: 29743605
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Sci Rep. 2018 Aug 13;8(1):12020
pubmed: 30104699
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cells. 2018 Oct 13;7(10):null
pubmed: 30322133
Stem Cells Int. 2018 Nov 5;2018:6392198
pubmed: 30532788
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094